Sciex’s recently launched accurate mass instrument, the ZenoTOF 7600 system, offers novel ion fragmentation and increased sensitivity for life science research and biotherapeutic development.
The ZenoTOF 7600 System, recently launched by Sciex in June 2021, is a mass liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) instrument that includes both Zeno trap and electron activated dissociation (EAD) fragmentation.
This new system enables scientists to better identify, characterize, and quantify molecules by generating data that has been previously unattainable, Sciex stated in a company press release. These capabilities are expected to help solve real analytical challenges and advance the development of new precision diagnostics and biotherapeutics.
Zeno trap pulsing delivers up to twenty times more sensitivity than traditional orthogonal time-of-flight technology, while EAD fragmentation can derive novel structural information from diverse compound types. With EAD fragmentation, the system can fully characterize individual lipids from a single spectrum, which can enable the discovery of novel lipid markers for cancer and inflammatory disease. EAD fragmentation also allows biopharma scientists to precisely detect and quantify protein glycosylation patterns and differentiate isomeric amino acids, which are both critical for ensuring that therapies are safe and do not produce adverse reactions.
Additionally, when compared to prior products, this new LC–MS/MS system can quantify up to 40% more proteins and analyze biobank samples five times faster, Sciex stated in the press release.
Source: Sciex
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.